Crude Oil Prices Rise as US Homebuilder Confidence Falls in August
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 18 2025
0mins
Source: Benzinga
U.S. Stock Market Performance: U.S. stocks declined with the Nasdaq Composite down 0.2%, Dow down 0.02%, and S&P 500 down 0.09% during Monday's trading session.
Sector Movements: Industrials sector saw a rise of 0.3%, while communication services stocks fell by 1%.
Housing Market Index: The NAHB/Wells Fargo Housing Market Index decreased to 32 in August from 33 in July, below market expectations of 34.
Notable Stock Movements: Propanc Biopharma surged 119% after uplisting to Nasdaq; Aspire Biopharma rose 57% due to positive trial results; meanwhile, Tonix Pharmaceuticals dropped 22% following FDA approval for its fibromyalgia treatment.
Analyst Views on PPCB
About PPCB
Propanc Biopharma, Inc. is an Australia-based biopharmaceutical company. The Company is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development. Its drug pipeline also includes POP1.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
